The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson’s disease: an observational study

BACKGROUND: Dopamine agonists (DA) are the first-choice drug for treatment of the early stage of Parkinson’s disease (PD) in subjects younger than 70 years. Recently, a number of third generation DA have been marketed, including transdermal patch of rotigotine and extended release oral formulation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellicano, Clelia, Benincasa, Dario, Fanciulli, Alessandra, Latino, Pamela, Giovannelli, Morena, Pontieri, Francesco E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880455/
https://www.ncbi.nlm.nih.gov/pubmed/24360350
http://dx.doi.org/10.1186/2047-783X-18-60

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880455/
https://www.ncbi.nlm.nih.gov/pubmed/24360350
http://dx.doi.org/10.1186/2047-783X-18-60

Ejemplares similares